Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

BMC Neurology

Hirofumi Matsuyama¹  Hidekazu Tomimoto¹  Yamato Nishiguchi¹  Akihiro Shindo¹  Kuniko Maeda² 

[1] Department of Neurology, Graduate School of Medicine, Mie University, 514-8507, Tsu, Mie, Japan;Department of Ophthalmology, Mie Prefectural Shima Hospital, 517-0595, Shima, Mie, Japan;

关键词: Miller fisher syndrome;    Guillain–Barré syndrome;    SARS-CoV-2;    COVID-19;    Vaccination;   

DOI  :  10.1186/s12883-021-02489-x

来源: Springer

【 摘 要 】

BackgroundThe coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. One of the vaccines approved against COVID-19 is the BNT162b2 mRNA COVID-19 vaccine (Pfizer/BioNTech).Case presentationWe present the case of a 71-year-old man with no history of the SARS-CoV-2 infection or any recent viral or bacterial illnesses who presented with bilateral oculomotor palsy and limb ataxia after BNT162b2 mRNA COVID-19 vaccination. The diagnosis of Miller Fisher syndrome (MFS) was established based on physical examination, brain magnetic resonance imaging (MRI), cerebrospinal fluid analysis (CSF), and positron emission tomography (PET). There was no evidence of other predisposing infectious or autoimmune factors, and the period from COVID-19 vaccination to the appearance of neurological symptoms was similar to that of other vaccines and preceding events, such as infection.ConclusionGuillain–Barré syndrome (GBS) and its variants after COVID-19 vaccination are extremely rare. Note that more research is needed to establish an association between MFS and COVID-19 vaccines. In our opinion, the benefits of COVID-19 vaccination largely outweigh its risks.

【 授权许可】

CC BY